Indefinite Delivery Contract SPE2DU25D9540

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is issuing a solicitation to establish Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), United States Coast Guard, and other designated providers. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. This will be an unrestricted and fully competitive acquisition, with awards made to the responsive and responsible offerors whose proposals are technically acceptable and offer the lowest overall price based on distribution fees.

The DLA has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, under the SPE2DB program. The $499,999,999 IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.